智通财经网·2025-08-27 09:36Core Viewpoint - The company, Zhaoyan New Drug (06127), has approved an investment of up to 8 million RMB in a private equity fund focused on brain science and related medical technologies [1] Investment Details - The investment will be made through the company's wholly-owned subsidiary, Beijing Zhaoyan Management Technology Co., Ltd., in collaboration with Beijing Chongde Yingsheng Investment Management Co., Ltd. and other partners [1] - The fund will primarily invest in new-generation medical devices, consumables, and drugs for the diagnosis and treatment of brain diseases [1] - The fund aims to prioritize investments in early-stage small and medium-sized enterprises located in the Changping area, with at least 50% of the total investment amount allocated to these enterprises [1]